Capricor Therapeutics, Inc.
HealthcareNASDAQ:CAPR · NASDAQ Global Select
+$0.76 today
Vol 0.77M · Avg 1.11M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-34.4%
avg 70.7%
ROIC
-33.1%
avg -87.7%
ROA
-29.5%
avg -57.8%
Analysis
ROA is currently the strongest return metric at -29.5% versus its period average of -57.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Anthony J. Bergmann | Chief Financial Officer & Corporate Treasurer | $584,750.00 | — | 40 | $11,223.00 | 0.02% |
Linda Marbán | Co-Founder, President, Chief Executive Officer & Director | $580,645.00 | — | 63 | $100,000.00 | 0.22% |
Karen G. Krasney | Executive Vice President, General Counsel & Secretary | $500,718.00 | — | 73 | $55,547.00 | 0.12% |
Frank Isaac Litvack FACC | Executive Chairman of the Board | $120,000.00 | — | 70 | $0.00 | <0.01% |
Kristi A. H. Elliott | Chief Operating & Science Officer | — | — | — | $842,439.00 | 1.84% |
Mark Awadalla | Chief Development Officer | — | — | — | — | — |
Minghao Sun | Senior Vice President of Quality Control, Research & Product Development | — | — | — | — | — |
Nathaniel Hogan | Director of Biostatistics of Capricor Therapeutics | — | — | — | — | — |
Catherine Lee Kelleher | Consultant | — | — | — | — | — |
Micheal Binks | Chief Medical Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
7
$6.85M
Net Sentiment
$6.85M
Net selling
Most Active
Sabar Karimah Es
3 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 7 sells worth $6.85M over the last 12 months. That adds up to net selling of $6.85M. Sabar Karimah Es was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +168.3% | +40.6% (15yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +168.3% over three years. Forward estimates point to Revenue at +40.6% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Achieve Life Sciences, Inc.
NASDAQ:ACHV
$566.68M
Cabaletta Bio, Inc.
NASDAQ:CABA
$490.79M
Allogene Therapeutics, Inc.
NASDAQ:ALLO
$463.35M
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
$353.00M
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
$343.14M
Entrada Therapeutics, Inc.
NASDAQ:TRDA
$250.78M
Editas Medicine, Inc.
NASDAQ:EDIT
$244.75M
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
$198.11M
ProQR Therapeutics N.V.
NASDAQ:PRQR
$151.72M
Immutep Limited
NASDAQ:IMMP
$53.60M
Who manages CAPR?
Capricor Therapeutics, Inc. (CAPR) lists 10 active executives. The top listed executive is Karen G. Krasney, Executive Vice President, General Counsel & Secretary.
Are CAPR insiders buying or selling?
Recent insider activity shows net selling of $927.25M.
Explore More
Continue the stock analysis
Jump to another research area for this company.